Overcoming challenges in obesity medicine: The SURMOUNT Clinical Development Program
In this medfyle
Obesity is a major cause of patient morbidity and mortality. Tirzepatide, a GIP and GLP-1 agonist, reported potentially life-changing results for patients with obesity. The SURMOUNT trial reported high efficacy of tirzepatide, with substantial, clinically meaningful, and sustained body weight reduction, and a favourable safety and tolerability profile, with a very low proportion of patients reporting serious adverse events.
Expert commentary
About this Medfyle
This is a highlights summary of an oral session given at the EASD Annual Meeting 2022 and presented by:
Dr. Carel Le Roux
St. Vincent's University Hospital and University College Dublin
Dublin, Ireland
Dr. Ania M. Jastreboff
Yale University School of Medicine
New Haven, CT, USA
Dr. Luc van Gaal
Antwerp University Hospital
Edegem, Belgium
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Dr. Dimitri J Pournaras
North Bristol NHS Trust
Bristol, UK
